Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Standard Biotools Inc (LAB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/04/2025: LAB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -73.63% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 405.51M USD | Price to earnings Ratio - | 1Y Target Price 2.38 |
Price to earnings Ratio - | 1Y Target Price 2.38 | ||
Volume (30-day avg) 2004677 | Beta 1.53 | 52 Weeks Range 0.99 - 3.04 | Updated Date 04/5/2025 |
52 Weeks Range 0.99 - 3.04 | Updated Date 04/5/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.52 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -79.62% | Operating Margin (TTM) -29.42% |
Management Effectiveness
Return on Assets (TTM) -18.01% | Return on Equity (TTM) -43.75% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 145637407 | Price to Sales(TTM) 2.32 |
Enterprise Value 145637407 | Price to Sales(TTM) 2.32 | ||
Enterprise Value to Revenue 0.83 | Enterprise Value to EBITDA -19.22 | Shares Outstanding 378985984 | Shares Floating 48278496 |
Shares Outstanding 378985984 | Shares Floating 48278496 | ||
Percent Insiders 1.86 | Percent Institutions 73.11 |
Analyst Ratings
Rating 5 | Target Price 3.08 | Buy - | Strong Buy 3 |
Buy - | Strong Buy 3 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Standard Biotools Inc
Company Overview
History and Background
Standard Biotools Inc, formerly Fluidigm Corporation, was founded in 1999. It initially focused on microfluidics technology for life science research, evolving to provide tools for single-cell biology, genomics, and proteomics. The company rebranded to Standard BioTools in 2022.
Core Business Areas
- Mass Cytometry: Provides instruments and reagents for high-parameter single-cell analysis, allowing researchers to study cell populations with greater detail and throughput.
- Microfluidics: Offers microfluidic platforms for genomics and proteomics applications, including gene expression analysis, genotyping, and protein quantification.
- Biomarker Discovery: Assists in the identification and validation of biomarkers for various diseases and applications, enabling personalized medicine and diagnostics.
Leadership and Structure
The company is led by a CEO and executive team, with a board of directors overseeing corporate governance. Organizational structure typically includes departments for R&D, sales, marketing, operations, and finance.
Top Products and Market Share
Key Offerings
- Helios Mass Cytometer: A high-parameter single-cell analysis platform. Market share is estimated to be 20-30% in the mass cytometry market. Competitors include Cytek Biosciences (CTKB) and BD Biosciences.
- market_share: 25
- Biomark HD System: A microfluidic platform for gene expression analysis. Lacks significant market share due to competition from Thermo Fisher Scientific (TMO) and Illumina (ILMN).
- market_share: 1
Market Dynamics
Industry Overview
The life science tools industry is driven by advancements in genomics, proteomics, and cell biology. Key trends include single-cell analysis, personalized medicine, and automation.
Positioning
Standard Biotools Inc occupies a niche in single-cell analysis, with a strong presence in mass cytometry. However, it faces competition from larger, more diversified companies.
Total Addressable Market (TAM)
The total addressable market for single-cell analysis is estimated to be $5-10 billion. Standard Biotools Inc holds a small but significant portion of this TAM, with potential for growth in targeted segments.
Upturn SWOT Analysis
Strengths
- Strong technology in mass cytometry
- Established customer base in research institutions
- Proprietary microfluidics technology
Weaknesses
- Limited product diversification
- Smaller scale compared to major competitors
- Past financial underperformance
Opportunities
- Expansion into clinical diagnostics
- Partnerships with pharmaceutical companies
- Growth in emerging markets
Threats
- Intense competition from larger players
- Technological advancements from competitors
- Changes in research funding landscape
Competitors and Market Share
Key Competitors
- Thermo Fisher Scientific (TMO)
- Illumina (ILMN)
- Cytek Biosciences (CTKB)
- BD Biosciences (BDX)
Competitive Landscape
Standard Biotools Inc faces significant competition from larger, more diversified companies with greater financial resources and broader product portfolios. The company's strength lies in its mass cytometry technology, but it needs to improve its overall market position and financial performance.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been inconsistent, with periods of growth followed by declines.
Future Projections: Analyst estimates suggest potential for revenue growth. However, profitability remains a challenge.
Recent Initiatives: Recent strategic initiatives include focusing on core product lines, improving operational efficiency, and pursuing partnerships.
Summary
Standard Biotools Inc has valuable mass cytometry technology, but faces challenges due to limited diversification, smaller scale, and inconsistent financials. It operates in a competitive landscape dominated by larger players. Key opportunities involve expansion into clinical diagnostics and strategic partnerships. The company needs to improve profitability and execute its strategic initiatives to realize its growth potential.
Similar Companies
BDX
Becton Dickinson and Company
BDX
Becton Dickinson and Company
CTKB
Cytek Biosciences Inc
CTKB
Cytek Biosciences Inc
ILMN
Illumina Inc
ILMN
Illumina Inc
TMO
Thermo Fisher Scientific Inc
TMO
Thermo Fisher Scientific Inc
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Publications
- Company Press Releases
- Market Data
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Market conditions and company performance can change rapidly. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Standard Biotools Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2003-07-29 | President, CEO & Director Dr. Michael Egholm Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 814 | Website https://www.standardbio.com |
Full time employees 814 | Website https://www.standardbio.com | ||
Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through two segments: Proteomics and Genomics. It provides SomaScan platform that enables researchers to measure thousands of proteins simultaneously, providing deep insights into biological processes and disease mechanism; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system redefines high-throughput genomics by delivering exceptional efficiency, precision, and scalability for qPCR applications. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.